Cardinal Health reported fourth-quarter fiscal 2025 adjusted earnings of $2.08 a share, topping analysts’ $2.04 consensus, while revenue came in at $60.16 billion, slightly below the $60.92 billion expected. On a GAAP basis, diluted EPS was $1.00. Excluding the impact of a previously disclosed contract expiration, revenue rose 21% year-on-year, with operating earnings up 19% to $719 million as all five segments posted double-digit profit growth. The Dublin, Ohio–based drug distributor raised its non-GAAP earnings outlook for fiscal 2026 to $9.30–$9.50 a share from the $9.10–$9.30 range given in June and above the $9.26 analyst consensus. Management cited continued momentum in its Pharmaceutical and Specialty Solutions unit and recent acquisitions, including a definitive agreement to buy Solaris Health, a leading urology management services organization with more than 750 providers. "We enter fiscal 2026 with confidence," Chief Executive Officer Jason Hollar said, pointing to disciplined execution and planned share repurchases of about $750 million.